心力衰竭与直立性低血压的相关性研究进展
Research Progress on the Correlation between Heart Failure and Orthostatic Hypotension
DOI: 10.12677/ACM.2023.134761, PDF, HTML, XML, 下载: 208  浏览: 419 
作者: 肖 丽:重庆医科大学附属第二医院老年医学科,重庆;陈庆伟*:重庆医科大学附属第二医院全科医学科,重庆
关键词: 心力衰竭直立性低血压Heart Failure Orthostatic Hypotension
摘要: 直立性低血压(orthostatic hypotension, OH)是心力衰竭(heart failure, HF)患者常见的共病。OH与HF的患病率随着年龄的增长而增加,伴随着人口老年化的加重,两者合并症将会更常见。有研究表明与无HF患者相比,OH在HF患者中患病率更高,OH可作为HF风险的早期标志物,且增加了HF的不良预后。OH和HF的疾病状态在一些方面是相互冲突的,使HF合并OH的治疗复杂化。因此,了解两者之间的病理生理、相关性及治疗,对改善OH症状及降低HF死亡率有重要临床意义,本文将对HF和OH的相关性研究做一综述。
Abstract: Orthostatic hypotension (OH) is a common comorbidity in patients with heart failure (HF). The prevalence of OH and HF increases with age, and symptoms of heart failure combined with orthos-tatic hypotension will be more common as the population ages. Several studies have shown a higher prevalence of OH in patients with HF compared with those without HF, and OH can be used as an early marker of HF risk and increase the adverse prognosis of HF. Therefore, understanding the pathophysiology, correlation and treatment between HF and OH has important clinical significance for improving OH symptoms and reducing HF mortality. This paper will review the correlation studies between HF and OH.
文章引用:肖丽, 陈庆伟. 心力衰竭与直立性低血压的相关性研究进展[J]. 临床医学进展, 2023, 13(4): 5373-5379. https://doi.org/10.12677/ACM.2023.134761

1. 引言

心力衰竭(heart failure, HF)是一组以肺循环和(或)体循环淤血为主要表现的临床综合征。HF在全球广泛流行,美国心脏学会杂志于2014年公布的数据,全球约有2600万HF患者 [1] ,随着人口老龄化,HF患病率将持续上升 [2] 。HF本身是一种高度适应直立性不耐受的疾病,且在治疗过程中利尿剂和神经激素抑制剂的使用,常导致直立性低血压(OH)发生。HF中OH的患病率为8%~83%不等 [3] ,尽管部分OH无症状或症状较轻,但OH的存在独立的增加了HF的发生率及HF患者的再入院率 [4] [5] ,并且为全因死亡的危险因素 [6] 。OH可能对HF患者的症状和日常生活造成不利影响,并让HF的治疗复杂化 [7] ,为了更好的理解HF与OH的关系,本文将对两者之间的病理生理、相关性及治疗做一综述。

2. 直立性低血压概述

直立性低血压(OH)也称体位性低血压,是一种常见的心血管疾病,表现为站立时血压异常下降,现常用OH的诊断标准为从卧位改为站立后或直立倾斜至少60˚的角度3分钟内收缩压降低至少20 mmHg或舒张压降低至少10 mmHg,伴或不伴各种低灌注症状 [8] 。OH患病率随着年龄的增长而增加,在30岁以上的患者中约为65% [9] 。大部分OH患者无症状 [10] ,OH的症状因诱发因素较多而缺乏特异性,例如:血压下降明显引起大脑自动调节失效,这将导致脑灌注受损,出现视物模糊、头晕、头痛、乏力、恶心、注意力障碍甚至晕厥 [11] ,肩颈部肌肉灌注不足会引起肩颈部疼痛,存在血管疾病或动脉狭窄时会导致相应部位缺血,出现心绞痛、腹痛等症状 [12] 。OH根据病理生理可分为神经源性OH和非神经源性OH两个亚型,神经源性OH主要特点是压力反射衰竭(自主神经功能衰竭),其病变分为中枢病变(如多系统萎缩、帕金森病)或周围神经系统疾病(如糖尿病、淀粉样变性),非神经源性OH主要由心输出量下降或血管代偿收缩功能障碍引起,其病因有血容量不足(如脱水、慢性失血、肾上腺皮质功能不全),心脏损伤(心律失常、主动脉瓣狭窄、心肌梗死),血管扩张(如严重静脉曲张、发热) [13] [14] 。已有研究表明OH与多种不良结局显著相关,例如跌倒、神经退行性疾病、心血管结局和死亡率 [9] [15] [16] [17] 。近年越来越多的证据表明,OH在识别HF发生风险及预后方面扮演重要角色。

3. HF与OH相关的病理生理机制

3.1. 直立反应机制

在正常人中,体位改变引起的血压波动通过压力感受性反射及神经体液反应调节可使血压维持正常水平。健康的个体从仰卧姿势转变为站立姿势时,血液(约半升至一升)从上半身转移到下肢和腹部循环中,下肢血液快速淤积引起静水压力的增加,将血浆液转移到周围组织中,这导致静脉回流降低,右心室充盈压降低,心排血量减少,最终血压下降,此时主动脉及颈动脉压力感受器检测到血压下降的变化,压力感受性反射减弱,导致心交感紧张和交感缩血管紧张增加,心迷走紧张减弱,引起心输出量增多,外周阻力增大,心率加快,血压回升 [18] [19] ,以上变化可使收缩压下降不超过10 mmHg,心率适度增加10~20次 [20] 。此外,站立时引起的血压下降,机体可通过神经体液反应调节,如激活肾素一血管紧张素一醛固酮系统,站立时,肾脏血流灌注减少,血浆Na+浓度降低,交感神经兴奋,近球细胞合成和分泌肾素增多,促使血管紧张素原转化为血管紧张素I,血管紧张素I可由血管紧张素转换酶转化为血管紧张素II,血管紧张素II具有缩血管作用,它还能促进肾上腺皮质分泌醛固酮,参与水盐调节,使血容量增加。并且站立时,右心房充盈压下降,加压素释放增加,心房钠肽分泌减少,加压素可促进周围血管收缩,心房钠肽的减少可降低其扩张血管、利尿排钠的作用。通过上述机制可维持正常的血压水平 [12] [21] 。

3.2. HF中OH的发病机制

HF中的容量状态和自主神经功能障碍是导致OH的主要病理生理驱动因素 [22] 。1) 心脏结构与功能异常可能引起OH [22] :① 当左心室收缩储备减少、左心室僵硬度增加及腔内高充盈压时,将导致心脏前负荷降低,静脉回心血量减少,最终心输出量减少。② 右心室储备异常、三尖瓣反流和肺压升高引起心输出量下降也可能导致直立性不耐受 [23] 。2) HF相关药物的使用可能导致OH [24] :① 利尿剂会增加尿钠排泄,诱发容量耗竭,此外,袢利尿剂可增加静脉容量,从而减少静脉回流和心排血量。② β受体阻滞剂具有负性肌力和变时性作用,可能会干扰站立时的代偿反应(交感神经介导的血管收缩和心率反应的增加和肌力变性)。③ 硝酸盐类具有舒张血管的作用,血管舒张主要涉及静脉区,因此减少静脉回流,并可能损害直立性血压。3) 机体老化导致压力反射钝化可能引起OH [3] :随着年龄增长,颈动脉和主动脉压力感受器的敏感性降低,压力感受器冲动形成障碍,将引起心率反应减弱、肾上腺素能血管收缩减弱。周围肌肉力量降低可能导致OH [25] [26] :下半身肌肉的收缩(即“肌肉泵”)可防止过多的血液在静脉血管中聚集,有利于静脉回流到心脏,然而HF患者典型的厌食、营养不良、活动体力活动减少等表现及HF本身的炎症反应将导致肌肉减少症 [27] [28] [29] 。肌肉减少使周围肌肉力量降低,从而静脉回心血量减少,这为心衰患者的直立不耐受提供了另一种机制。

4. HF与OH的相关性

4.1. HF对OH的影响

Zhu等人关于直立性低血压在亚洲人群中流动老年人的患病率的研究中,发现354名非HF患者与10名HF患者中OH的患病率分别为10%和30% [30] 。Weiss [31] 等人报道了从急性老年病房出院的147名HF患者中26%的OH患病率,而非HF患者中OH患病率为38%,两者的OH患病率具有可比性(P = 0.01)。在一项多中心随机对照试验中,OH在有HF病史的患者更常见,HF患者(306人)与非HF患者(8356人)中OH的诊断率(分别为13.7%和7.1%) [32] 。从上述研究中我们发现HF与OH风险增加有关,HF可能是OH的危险因素。

4.2. OH对HF的影响

在最近的一项前瞻性观察队列研究中,结果显示与无OH受试者相比,OH受试者具有更高的HF风险(HR: 1.47, 95%CI: 1.13~1.91),且OH与较高的HFrEF风险相关(HR: 2.21, 95%CI: 1.34~3.67),OH可作为HF风险的早期标志物 [33] 。这与之前的两篇文献报道的结果类似 [5] [34] ,OH可增加HF患病风险。一项研究是基于瑞典人群的前瞻性研究,发现患有OH的1991名患者,随访期间有1293名患者因HF住院,在多变量Cox比例风险模型中,考虑到常规HF危险因素,OH与HF事件相关(HR: 1.22, 95%CI: 1.01~1.46) [34] 。另一项前瞻性观察性研究的荟萃分析,共纳入了来自51,270个前瞻性队列的3603名受试者和4例CHF事件病例。最后结果显示有OH的患者与未来HF结局的风险增加显着相关(HR: 1.30, 95%CI: 1.09~1.55, P = 0.004) [5] 。此外,OH在HF预后方面也有相关的文献报道,吕逸宁等人的研究中,在300例老年HF患者中,平均随访(28.3 ± 15.4)个月,Kaplan-Meier生存分析提示,有OH组因HF再入院(27.0% vs 11.5%, P = 0.001)、卒中(6.0% vs 2.0%, P = 0.037)和不良心脑血管事件发生率(53.0% vs 27.0%, P < 0.001)均显著高于无OH组的患者,最终表明OH可显著增加老年HF患者的再入院率和卒中发生风险,且为不良心脑血管事件的独立危险因素 [4] 。在控制糖尿病心血管风险的行动血压试验中,与无OH的个体相比,OH患者心力衰竭死亡或住院的风险增高(HR: 1.85, 95%CI: 1.17~2.93, P = 0.01) [35] 。庹必祥 [36] 等人报道了32例老年HF患者OH后猝死的病案分析,全部老年HF患者除病因治疗外均予正规的抗HF药物治疗,在治疗过程中出现OH,随后患者发生猝死,因此,我们需要提高HF患者中OH的诊断,高度重视OH对HF带来的不良影响。

5. HF合并OH的治疗

OH和HF的疾病状态在一些方面是相互冲突的,例如HF的治疗目标是降低死亡率,主要为限制盐和液体、减少后负荷和神经激素阻断的治疗。而OH的治疗目标是改善症状提高生活质量,侧重于增加盐和液体负荷、收缩血管、激活交感神经的治疗。因此,HF和OH治疗面临一些挑战。OH的治疗分为非药物及药物治疗。非药物治疗分为患者教育及物理治疗,药物治疗包括米多君、屈昔多巴、氟氢可的松、吡啶斯的明等,但只有米多君、屈昔多巴是美国食品和药物管理局批准的唯一用于OH治疗的药物。由于一些OH的治疗药物可能会对HF有负面影响及HF的一些治疗药物本身有导致OH风险,所以HF合并OH的治疗可分为非药物治疗、HF治疗药物的调整及OH药物的选择。

5.1. 非药物治疗

日常生活方面:采用头比脚高15~23厘米的仰卧睡姿 [37] ,有助促进静脉回流。同时建议起床时动作缓慢,能有效减少血压下降幅度,避免OH发生 [38] 。适当增加下肢肌肉锻炼,长期处于静止状态时骨骼肌“肌肉泵”的作用会减弱,不利于静脉血回流到心脏,容易引起OH。避免长期处于湿热的环境中,湿热环境里会引起血管舒张,从而引起或加重OH [39] 。物理治疗:站立引起的下肢和内脏循环中的静脉淤积可以通过物理压迫来对抗,使用腹部粘合剂或穿医用弹力袜促进静脉回流,可限制站立时血压的下降 [40] [41] 。

5.2. HF治疗药物的调整

HF治疗中常有用的血管紧张素受体脑啡肽酶抑制剂、血管紧张素转换酶抑制剂、醛固酮拮抗剂和β受体阻滞剂具有降低后负荷和神经激素阻断作用,在可行的情况下可以去除或减少上述药物有助于改善血管内容量和全身血管阻力,从而减轻直立症状 [42] 。其中关于β受体阻滞剂的使用,可选择β1选择性受体拮抗剂(如琥珀酸美托洛尔)代替非选择性β和α1受体拮抗剂(如卡维地洛),因为α受体拮抗可舒张血管,从而导致直立性症状。利尿剂作为HF容量管理的主要药物,可增加尿钠排泄,减轻HF相关症状,不适当的剂量可能导致低血容量而导致OH,应根据患者的实际情况减量或停用。

5.3. OH药物的选择

米多君是一种外周α肾上腺素能激动剂,其作用为血管收缩和增加周围血管阻力,从而导致血压升高,改善了站立能力,具有良好的耐受性 [43] ,被美国食品和药物管理局批准用于OH的治疗。但米多君可增加后负荷,在HF中需谨慎使用 [39] 。然而,既往的一篇文献报道了米多君在伴有低血压的HF中具有良好的耐受性,并改善了左心室射血分数和临床结果 [44] 。因此米多君在HF患者中能否使用,需仔细对患者整体情况评估后进行个体化抉择。

屈昔多巴是一种去甲肾上腺素前体药物,可在人体内转化为去甲肾上腺素从而促进血管收缩,可有效减轻神经源性OH症状,具有良好耐受性 [45] ,是一种被美国食品和药物管理局批准用于OH治疗的药物。但曲昔多巴诱发外周血管收缩可能加重现有的缺血性心脏病、心律失常和HF [39] 。然而,在一项双盲安慰剂对照研究(n = 350,曲昔多巴暴露的平均持续时间为363天)中,该疗法与心血管不良事件风险增加无关。

氟氢可的松是一种人工合成的具有盐皮质激素作用的类固醇,通过水钠潴留增加血管内容积来增加血压,已被证明在OH中可改善直立症状并增加直立性血压 [46] 。氟氢可的松有体液过载风险,在HF中应谨慎使用,在一项回顾性队列研究中(1324名患者使用氟氢可的松,797名患者使用米多君),氟化可的松与米多君相比,全因住院率更高,尤其是有HF病史的患者中。然而,氟氢可的松在美国食品和药物管理局的处方信息中未被列为是HF的禁忌症,如果已经探索了所有HF合并OH治疗的替代策略,在减轻症状方面都不成功,使用氟氢可的松可能对神经源性OH和HF患者有一定的益处 [42] 。

吡啶斯的明是一种胆碱酯酶抑制剂,通过阻止乙酰胆碱的代谢来增强胆碱能交感神经节传导,可间接诱发血压升高 [47] ,能够改善直立性血压下降 [48] [49] 。吡啶斯的明不会导致体液潴留及明显的血管收缩(仅能够使收缩压升高4 mmHg) [14] ,因此,可能适合在HF患者中使用,但仍需大样本前瞻性研究进一步验证。

综上所述,治疗OH的药物有加重HF的风险,少量文献报道OH治疗药物用于HF合并OH的患者中可能有一定益处。HF患者病因复杂多样,且合并的OH症状严重程度不等,需对HF合并OH的患者进行个性化管理,非药物治疗应为首选,可多学科协作,整体评估患者情况后,在改善生活质量和降低心衰死亡率之间找到微妙平衡进行HF药物的调整及OH治疗药物的选择。

6. 小结

随着人口老龄化加重,HF与OH的患病率将增加。OH是HF的常见共病,HF合并OH对患者预后产生了重要的影响,OH症状往往缺乏特异性,HF中的OH在临床实践中常被忽视,需提高HF中OH的诊断。OH和HF的疾病状态在一些方面是相互冲突的,应该对HF合并OH的患者进行个体化管理。HF中OH的病理生理机制复杂,且HF合并OH的药物选择仍面临挑战,值得人们进一步探索。

NOTES

*通讯作者。

参考文献

[1] Ambrosy, A.P., Fonarow, G.C., Butler, J., et al. (2014) The Global Health and Economic Burden of Hospitalizations for Heart Failure: Lessons Learned from Hospitalized Heart Failure Registries. Journal of the American College of Cardiolo-gy, 63, 1123-1133.
https://doi.org/10.1016/j.jacc.2013.11.053
[2] Virani, S.S., Alonso, A., Aparicio, H.J., et al. (2021) Heart Disease and Stroke Statistics-2021 Update: A Report from the American Heart Association. Circulation, 143, e254-e743.
https://doi.org/10.1161/CIR.0000000000000950
[3] Gorelik, O., Feldman, L. and Cohen, N. (2016) Heart Failure and Orthostatic Hypotension. Heart Failure Reviews, 21, 529-538.
https://doi.org/10.1007/s10741-016-9541-z
[4] 吕逸宁, 朱琳, 靳博华, 等. 体位性低血压对老年心力衰竭患者长期预后的影响[J]. 中国心血管杂志, 2021, 26(2): 142-146.
[5] Xin, W., Lin, Z. and Li, X. (2013) Orthostatic Hypotension and the Risk of Congestive Heart Failure: A Meta-Analysis of Prospective Cohort Studies. PLOS ONE, 8, e63169.
https://doi.org/10.1371/journal.pone.0063169
[6] Farrell, M.C. and Shibao, C.A. (2020) Morbidity and Mortality in Orthostatic Hypotension. Autonomic Neuroscience: Basic & Clinical, 229, Article ID: 102717.
https://doi.org/10.1016/j.autneu.2020.102717
[7] Ricci, F., De Caterina, R. and Fedorowski, A. (2015) Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. Journal of the American College of Cardiology, 66, 848-860.
https://doi.org/10.1016/j.jacc.2015.06.1084
[8] The Consensus Committee of the American Autonomic Society and the American Academy of Neurology (1996) Consensus Statement on the Definition of Orthostatic Hypotension, Pure Autonomic Failure, and Multiple System Atrophy. Neurology, 46, 1470.
https://doi.org/10.1212/WNL.46.5.1470
[9] Michon, P.L., Kahn, J.E., Picart, C., et al. (2022) Orthostatic Hypo-tension: Focus on a Common Pathology Sometimes Misknowned. Geriatrie et Psychologie Neuropsychiatrie du Vieillissement, 20, 421-428.
https://doi.org/10.1684/pnv.2022.1063
[10] Benvenuto, L.J. and Krakoff, L.R. (2011) Morbidity and Mortality of Orthostatic Hypotension: Implications for Management of Cardiovascular Disease. American Journal of Hypertension, 24, 135-144.
https://doi.org/10.1038/ajh.2010.146
[11] Novak, V., Novak, P., Spies, J.M., et al. (1998) Autoregulation of Cere-bral Blood Flow in Orthostatic Hypotension. Stroke, 29, 104-111.
https://doi.org/10.1161/01.STR.29.1.104
[12] Joseph, A., Wanono, R., Flamant, M., et al. (2017) Orthostatic Hy-potension: A Review. Nephrologie & Therapeutique, 13, S55-S67.
https://doi.org/10.1016/j.nephro.2017.01.003
[13] Figueroa, J.J., Basford, J.R. and Low, P.A. (2010) Preventing and Treating Orthostatic Hypotension: As Easy as A, B, C. Cleveland Clinic Journal of Medicine, 77, 298-306.
https://doi.org/10.3949/ccjm.77a.09118
[14] 汪贻熙, 王雨, 董一飞. 体位性低血压诊断和治疗研究进展[J]. 中华高血压杂志, 2021, 29(10): 923-929.
[15] Kim, M.J. and Farrell, J. (2022) Orthostatic Hypotension: A Practical Ap-proach. American Family Physician, 105, 39-49.
[16] Wiersinga, J.H.I., Muller, M., Rhodius-Meester, H.F.M., et al. (2022) Orthostatic Hypotension and Mortality Risk in Geriatric Outpatients: The Impact of Duration and Magnitude of the Blood Pressure Drop. Journal of Hypertension, 40, 1107-1114.
https://doi.org/10.1097/HJH.0000000000003097
[17] Min, M., Shi, T., Sun, C., et al. (2020) The Association be-tween Orthostatic Hypotension and Cognition and Stroke: A Meta-Analysis of Prospective Cohort Studies. Blood Pres-sure, 29, 3-12.
https://doi.org/10.1080/08037051.2019.1689808
[18] Smit, A.A., Halliwill, J.R., Low, P.A., et al. (1999) Patho-physiological Basis of Orthostatic Hypotension in Autonomic Failure. The Journal of Physiology, 519, 1-10.
https://doi.org/10.1111/j.1469-7793.1999.0001o.x
[19] Jacob, G., Ertl, A.C., Shannon, J.R., et al. (1998) Effect of Standing on Neurohumoral Responses and Plasma Volume in Healthy Subjects. Journal of Applied Physiology (Bethesda, Md: 1985), 84, 914-921.
https://doi.org/10.1152/jappl.1998.84.3.914
[20] Mar, P.L. and Raj, S.R. (2018) Orthostatic Hypotension for the Cardiologist. Current Opinion in Cardiology, 33, 66-72.
https://doi.org/10.1097/HCO.0000000000000467
[21] Nilsson, D., Sutton, R., Tas, W., et al. (2015) Orthostatic Changes in Hemodynamics and Cardiovascular Biomarkers in Dysautonomic Patients. PLOS ONE, 10, e0128962.
https://doi.org/10.1371/journal.pone.0128962
[22] Soloveva, A., Fedorova, D., Villevalde, S., et al. (2020) Ad-dressing Orthostatic Hypotension in Heart Failure: Pathophysiology, Clinical Implications and Perspectives. Journal of Cardiovascular Translational Research, 13, 549-569.
https://doi.org/10.1007/s12265-020-10044-1
[23] Morris, R.I., Sobotka, P.A., Balmforth, P.K., et al. (2020) Ili-ocaval Venous Obstruction, Cardiac Preload Reserve and Exercise Limitation. Journal of Cardiovascular Translational Research, 13, 531-539.
https://doi.org/10.1007/s12265-020-09963-w
[24] Rivasi, G., Rafanelli, M., Mossello, E., et al. (2020) Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications. Drugs & Aging, 37, 725-738.
https://doi.org/10.1007/s40266-020-00796-5
[25] Keskin, K., Çiftçi, S., Öncü, J., et al. (2021) Orthostatic Hypo-tension and Age-Related Sarcopenia. Turkish Journal of Physical Medicine and Rehabilitation, 67, 25-31.
https://doi.org/10.5606/tftrd.2021.5461
[26] Soysal, P., Kocyigit, S.E., Dokuzlar, O., et al. (2020) Relationship be-tween Sarcopenia and Orthostatic Hypotension. Age and Ageing, 49, 959-965.
https://doi.org/10.1093/ageing/afaa077
[27] Collamati, A., Marzetti, E., Calvani, R., et al. (2016) Sarcopenia in Heart Failure: Mechanisms and Therapeutic Strategies. Journal of Geriatric Cardiology: JGC, 13, 615-624.
[28] Galvan, E., Arentson-Lantz, E., Lamon, S., et al. (2016) Protecting Skeletal Muscle with Protein and Amino Acid during Periods of Disuse. Nutrients, 8, 404.
https://doi.org/10.3390/nu8070404
[29] Ilhan, B., Bahat, G., Erdoğan, T., et al. (2019) Anorexia Is Independently Associated with Decreased Muscle Mass and Strength in Community Dwelling Older Adults. The Journal of Nutrition, Health & Aging, 23, 202-206.
https://doi.org/10.1007/s12603-018-1119-0
[30] Zhu, Q.O., Tan, C.S., Tan, H.L., et al. (2016) Orthostatic Hypo-tension: Prevalence and Associated Risk Factors among the Ambulatory Elderly in an Asian Population. Singapore Med-ical Journal, 57, 444-451.
https://doi.org/10.11622/smedj.2016135
[31] Weiss, A., Beloosesky, Y., Kornowski, R., et al. (2006) Influence of Orthostatic Hypotension on Mortality among Patients Discharged from an Acute Geriatric Ward. Journal of General In-ternal Medicine, 21, 602-606.
https://doi.org/10.1111/j.1525-1497.2006.00450.x
[32] Townsend, R.R., Chang, T.I., Cohen, D.L., et al. (2016) Orthostatic Changes in Systolic Blood Pressure among SPRINT Participants at Baseline. Journal of the American Society of Hypertension: JASH, 10, 847-856.
https://doi.org/10.1016/j.jash.2016.08.005
[33] Shrout, T.A., Pan, S., Mitchell, G.F., et al. (2022) Association of Orthostatic Blood Pressure Response with Incident Heart Failure: The Framingham Heart Study. PLOS ONE, 17, e0267057.
https://doi.org/10.1371/journal.pone.0267057
[34] Fedorowski, A., Engström, G., Hedblad, B., et al. (2010) Orthostatic Hypotension Predicts Incidence of Heart Failure: the Malmö Preventive Project. American Journal of Hypertension, 23, 1209-1215.
https://doi.org/10.1038/ajh.2010.150
[35] Fleg, J.L., Evans, G.W., Margolis, K.L., et al. (2016) Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. Hypertension (Dallas, Tex: 1979), 68, 888-895.
https://doi.org/10.1161/HYPERTENSIONAHA.116.07474
[36] 庹必祥, 阮明珠, 王燕. 老年心力衰竭直立性低血压后猝死32例分析[J]. 疑难病杂志, 2008, 7(1): 41-42.
[37] Gibbons, C.H., Schmidt, P., Biaggioni, I., et al. (2017) The Recommendations of a Consensus Panel for the Screening, Diagnosis, and Treatment of Neurogenic Orthos-tatic Hypotension and Associated Supine Hypertension. Journal of Neurology, 264, 1567-1582.
https://doi.org/10.1007/s00415-016-8375-x
[38] De Bruïne, E.S., Reijnierse, E.M., Trappenburg, M.C., et al. (2017) Standing Up Slowly Antagonises Initial Blood Pressure Decrease in Older Adults with Orthostatic Hypotension. Geron-tology, 63, 137-143.
https://doi.org/10.1159/000450642
[39] Palma, J.A. and Kaufmann, H. (2020) Management of Orthostatic Hypo-tension. Continuum (Minneapolis, Minn), 26, 154-177.
https://doi.org/10.1212/CON.0000000000000816
[40] Podoleanu, C., Maggi, R., Brignole, M., et al. (2006) Lower Limb and Abdominal Compression Bandages Prevent Progressive Orthostatic Hypotension in Elderly Persons: A Ran-domized Single-Blind Controlled Study. Journal of the American College of Cardiology, 48, 1425-1432.
https://doi.org/10.1016/j.jacc.2006.06.052
[41] Figueroa, J.J., Singer, W., Sandroni, P., et al. (2015) Effects of Pa-tient-Controlled Abdominal Compression on Standing Systolic Blood Pressure in Adults with Orthostatic Hypotension. Archives of Physical Medicine and Rehabilitation, 96, 505-510.
https://doi.org/10.1016/j.apmr.2014.10.012
[42] Dixon, D.D. and Muldowney, J.A.S. (2020) Management of Neu-rogenic Orthostatic Hypotension in the Heart Failure Patient. Autonomic Neuroscience: Basic & Clinical, 227, Article ID: 102691.
https://doi.org/10.1016/j.autneu.2020.102691
[43] Fouad-Tarazi, F.M., Okabe, M. and Goren, H. (1995) Alpha Sympathomimetic Treatment of Autonomic Insufficiency with Orthostatic Hypotension. The American Journal of Medi-cine, 99, 604-610.
https://doi.org/10.1016/S0002-9343(99)80246-0
[44] Zakir, R.M., Folefack, A., Saric, M., et al. (2009) The Use of Midodrine in Patients with Advanced Heart Failure. Congestive Heart Failure (Greenwich, Conn), 15, 108-111.
https://doi.org/10.1111/j.1751-7133.2008.00042.x
[45] Strassheim, V., Newton, J.L., Tan, M.P., et al. (2016) Droxidopa for Orthostatic Hypotension: A Systematic Review and Meta-Analysis. Journal of Hypertension, 34, 1933-1941.
https://doi.org/10.1097/HJH.0000000000001043
[46] Ten Harkel, A.D., Van Lieshout, J.J. and Wieling, W. (1992) Treatment of Orthostatic Hypotension with Sleeping in the Head-Up Tilt Position, Alone and in Com-bination with Fludrocortisone. Journal of Internal Medicine, 232, 139-145.
https://doi.org/10.1111/j.1365-2796.1992.tb00563.x
[47] Eschlböck, S., Wenning, G. and Fanciulli, A. (2017) Evi-dence-Based Treatment of Neurogenic Orthostatic Hypotension and Related Symptoms. Journal of Neural Transmission (Vienna, Austria: 1996), 124, 1567-1605.
https://doi.org/10.1007/s00702-017-1791-y
[48] Byun, J.I., Moon, J., Kim, D.Y., et al. (2017) Efficacy of Single or Combined Midodrine and Pyridostigmine in Orthostatic Hypotension. Neurology, 89, 1078-1086.
https://doi.org/10.1212/WNL.0000000000004340
[49] Singer, W., Sandroni, P., Opfer-Gehrking, T.L., et al. (2006) Pyridostigmine Treatment Trial in Neurogenic Orthostatic Hypotension. Archives of Neurology, 63, 513-518.
https://doi.org/10.1001/archneur.63.4.noc50340